Nuance hands off 2 business units, leans hard into conversational AI

A new company called DeliverHealth Solutions is forming to service clients of Nuance’s HIM transcription and EHR go-live businesses.

Nuance is selling the units primarily to concentrate on attaining and sustaining market leadership in the booming conversational AI space, according to an announcement.

Nuance will remain close to existing customers of these product lines, however, since it will be a minority shareholder and technology partner of DeliverHealth.

The new independent entity is formed by the joining of two companies—the private equity firm Assured Healthcare Partners and the outsourcing outfit Aeries Technology Group.  

In the announcement, Nuance says the development signals its continuing interest in healthcare and enterprise markets.

Nuance CEO Mark Benjamin adds that the three-company transaction reflects the ongoing “dramatic acceleration in the digital transformation of healthcare.”

Watch for the trend to continue, Benjamin suggests, “as organizations deploy the power of conversational AI and deeply integrated cloud-based solutions at scale to address physician burnout, expand patient access, and improve system efficiencies and the revenue cycle.”

Conversational AI is the branch focused on getting chatbots and other digital interfaces to talk to humans in natural speech patterns. The market for the technology has been forecast to top $18 billion by 2027, up from less than $5 billion in 2020.

At the sale’s closing, Michael Clark, currently a senior VP and GM with Nuance, will become DeliverHealth’s CEO.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.